Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : J&J Gets Subpoenas Related To Talc

share with twitter share with LinkedIn share with facebook
share via e-mail
02/21/2019 | 02:48am EDT

By Peter Loftus

Johnson & Johnson said Wednesday it received subpoenas from the U.S. Justice Department and the Securities and Exchange Commission seeking documents related to the safety of its signature baby powder and other talc-containing products.

A J&J spokesman said the inquiries were related to news reports in December about product-liability lawsuits against the company, which caused J&J's stock price to fall sharply. J&J disclosed the subpoenas in an annual report filed Wednesday with the SEC.

The company said it would cooperate with the government inquiries and continue to defend itself in the product-liability litigation.

Sales of Johnson's Baby Powder are relatively small for J&J, which recorded $81.6 billion in total company sales last year. Yet the product, one of the few branded with the company's name, plays an important role shaping J&J's reputation.

The talc-powder litigation threatens J&J's carefully cultivated image. At least 13,000 lawsuits against the company claim that use of Johnson's Baby Powder and other talc products caused ovarian cancer and mesothelioma, as the lawsuits allege.

J&J says decades of testing have shown its baby powder is safe and asbestos-free, and that it doesn't cause cancer.

J&J, based in New Brunswick, N.J., has won some of the lawsuits that went to trial, but some juries have awarded large amounts of money to plaintiffs, including $4.7 billion in July to 22 women and their families. J&J is appealing the verdicts.

A Reuters article in December said that J&J knew for decades that its talc powder contained asbestos, but the company concealed it from regulators and the public. J&J has disputed information in the article, saying the company has cooperated fully with regulators and the various methods used by the company, regulators and independent experts to test the cosmetic talc have confirmed it is safe and asbestos free.

J&J lost about $50 billion in market capitalization in the days following the Reuters report. The stock has recovered some, trading up 5.7% year-to-date and closing Wednesday at $136.35.

In January, Sen. Patty Murray, (D., Wash.), a member of the Senate Health, Education, Labor, and Pensions Committee, sent a letter to J&J CEO Alex Gorsky demanding information on what the company knew about potential asbestos in its talc products.

An SEC spokeswoman declined comment. The DOJ couldn't immediately be reached.

The American Cancer Society says some talc contains asbestos in its natural form, but talc used for cosmetic purposes is supposed to be free of detectable levels of asbestos. The organization says some studies have found a slightly increased risk of ovarian cancer in women who used talc powder, though other studies haven't found an increase.

Write to Peter Loftus at peter.loftus@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
05:46aJOHNSON & JOHNSON : FDA - Baby powder manufacturer voluntarily recalls products ..
05:45aJOHNSON & JOHNSON : Janssen Receives Positive CHMP Opinion for Spravato Nasal Sp..
01:12aJOHNSON & JOHNSON : Wall St drags on Boeing and Chinese data
12:35aJOHNSON & JOHNSON : 1st federal opioid crisis trial to focus on distribution
10/19JOHNSON & JOHNSON : J&J Recalls Baby Powder on Asbestos Concern -- 3rd Update
10/19J&J Recalls Baby Powder For Asbestos -- WSJ
10/18MARKET SNAPSHOT: Dow Ends Lower Pressured By Boeing, Johnson & Johnson, Despi..
10/18JOHNSON & JOHNSON : J&J Recalls Baby Powder on Asbestos Concern -- 2nd Update
10/18JPMORGAN CHASE, FACEBOOK, COCA-COLA : Stocks That Defined the Week
10/18CARDINAL HEALTH : Opioid negotiations fail to produce deal just before trial
More news
Financials (USD)
Sales 2019 82 226 M
EBIT 2019 25 622 M
Net income 2019 19 665 M
Debt 2019 7 881 M
Yield 2019 2,94%
P/E ratio 2019 17,8x
P/E ratio 2020 16,6x
EV / Sales2019 4,20x
EV / Sales2020 3,94x
Capitalization 338 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 149,16  $
Last Close Price 128,02  $
Spread / Highest target 35,1%
Spread / Average Target 16,5%
Spread / Lowest Target 0,77%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.05%337 021
ROCHE HOLDING AG18.88%250 869
MERCK AND COMPANY10.82%216 813
PFIZER-16.47%201 662
NOVARTIS15.10%198 751
NOVO NORDISK AS17.69%123 560